The design flaw is possibly related to the extremely small size of the implant wires. The Food and Drug Administration (FDA) was also aware of the alleged issue. Neuralink reportedly decided the risk was low enough and that a redesign wasn't necessary.
Despite potential non-functionality due to loose wires, Neuralink's decision not to redesign was influenced by the wires being easily removable without injury from the brain, part of the intentional design.
[
add
]
[
|
|
...
]